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Juvenile polyposis of infancy (OMIM 612242) 
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Juvenile polyposis of infancy (OMIM 612242) is a hamartomatous polyposis including 
macrocephaly, facial dysmorphism, hypotonia, developmental delay; rectal bleeding occurred 
during the first 2 years of life (1, 2). It results from a microdeletion of chromosome 10q23 
involving PTEN (phosphatase and tensing homolog) and BMPR1A (bone morphogenetic protein 
receptor type 1A) tumour-suppressor genes (1, 2). A protein-losing enteropathy can lead to 
colectomy in the first years of life (1, 2) and to an early death (2). Later on, there is an increased 
risk of colorectal cancer (2). 
In mice, the conditional deletion of Bmpr1a induces the development of numerous polyps 
mimicking human juvenile polyposis (3). BMP signalling promotes cell differentiation and thus 
balances the intestinal stem cell renewal under the control of the Wnt/Apc/-catenin pathway. In 
adenomatous polyposis coli (Apc) deficient mice, the inducible loss of Pten leads to an increased 
tumourigenesis because of an increased activation of PI3K/Akt/mTOR (phosphatidyl-inositol 3 
kinase/Protein kinase B/mammalian target of rapamycin) pathway (4).  
mTOR is a downstream effector of the PI3K negatively regulated by PTEN. Its expression is 
increased in intestinal polyps of Apc deficient mice; its inhibition reduced the number of polyps 
and their size (5), and also delayed the apparition of dysplasia (6). The wider use of the mTOR 
inhibitor sirolimus in clinical trials of cancer therapy and the severity of the phenotype of our 
young patient led us to consider this drug as a new therapeutic option.  
 
An 11-year old girl was followed since birth for macrocephaly (+5 SD), mild hypotonia, motor 
and developmental delay. When she was 18 months old, she had rectal bleeding. Her 
colonoscopy revealed numerous juvenile polyps, up to 3 cm of diameter (Figure 1 A, B). Genetic 
analysis found a de novo germline deletion encompassing PTEN and BMPR1A. Follow-up 
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endoscopies confirmed a severe form of polyposis with 30 to 50 polyps, mainly located in the 
colon but also in the stomach and the small bowel. She had a failure to thrive, mild anaemia and 
protein-losing enteropathy. A colonic perforation occurred after resection of large polyps when 
she was 5 years old. In emergency, a transient ileostomy was performed.  
 
Instead of performing a colectomy, which could exacerbate watery and stool losses and increase 
the risk of dehydration, we decided to start a treatment with sirolimus when she was 6-year-old, 
targeting a blood concentration of 5 ng/mL. We found a decrease in number and size of polyps 
during yearly endoscopic follow-up (Figure 1 C, D). After more than 4-year of follow-up, she 
showed a weight improvement and normal serum albumin level without recurrence of anaemia 
or adverse event. When she was 11-year-old no polyp was detected, even in the rectum where 
few small polyps were previously present.  
 
Importantly, an immunostaining of phospho-S6 ribosomal protein, a target of mTOR, showed a 
marked decreased expression after sirolimus initiation (Figure 2). 
In conclusion, this report suggests that sirolimus is effective in the treatment of severe juvenile 
polyposis of infancy and could be considered as a therapeutic option, instead of colectomy. 
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